Home

Contact Us

Anterior Ischemic Optic Neuropathy Treatment:

Anterior Ischemic Optic Neuropathy Treatment:

MAGNOVISION™ and Subtenon Bevacizumab + Platelet Rich Plasma Injection

Complaint: Decreased vision in the right eye after hypertensive crisis, blurred vision. Visual acuity 0.2;
Visual Field 42%, Papilla edema.

Treatment: 10 sessions of MAGNOVISION + 1st day, 1st week, 2nd week subtenon erythropoietin +
autologous PRP injection.

After 2 weeks, Visual acuity 0.7; Visual Field 88%, Papilla edema resolved.

Anterior Ischemic Optic Neuropathy Treatment:

Post COVID Optic Neuropathy Treatment: MAGNOVISION and Subtenon Erythropoietin + Platelet Rich
Plasma Injection.

Complaint: Decreased vision in the left eye after 1 week COVID pnömonia, blurred vision. Visual acuity 0.4;
Visual Field 56 %, cupping.

Treatment: 10 sessions of MAGNOVISION + 1st day, 1st week, 2nd week subtenon erythropoietin +
allogenically PRP injection.

After 2 weeks, Visual acuity 0.9; Visual Field 74%

postCOVID OPTIC NEUROPATHY: Post-COVID endotheliitis and microthrombi can cause optic neuropathy
and vision loss. Improvements were observed in visual acuity, visual field and patternERG after allogeneic
platelet rich plasma (PRP) + Eritropoetin + MAGNOVISION application.

PRP: A source of autologos growth factors and neurotrophins. PRP is the exosomes of bone marrow stem
cells in peripheral blood. Citrate in PRP provides liquefaction of the microthrombi. Growth factors and
Neurotrophins prevent the ganglion cells and optic nerve axons from ischemia-reperfusion damage.
Because of COVID antibodies circulating in the blood, PRP must be applied allogeneically, not autologously.

For PRP to be effective in retinal diseases, cooler centrifugal device and Magnovision electromagnetic
iontophoresis device must be used. To prevent denaturation of peptides in PRP content, PRP process must
be at +4 centrigrade, in citrated sterile PRP tubes and 8 minutes 2500 rpm with refrigerant centrifuge device

ERITROPOETIN: It is a growth factor that stimulates Erythropoiesis and Neurogenesis in the retina.

MAGNOVISION™: Accelerates neurotransmission and synaptic transmissions by activating ion channels
with neuromodulation. Electromagnetic iontophoresis device is mandatory for the transport of subtenon
PRP content from scleral pores to the choroidal matrix and then to the subretinal area by tyrosyn kinase
receptors.

Anterior Ischemic Optic Neuropathy Treatment:

METHYL ALCOHOL TOXIC OPTIC NEUROPATHY: In the case we applied MAGNOVISION and Wharton Jelly
Derived Mesenchymal Stemcell (WJ-MSC) after early dialysis, ethyl alcohol, erythropoetin, B1, B6, B12, Folic
acid administration in the intensive care unit, visual functions returned significantly. MAGNOVISION and
WJ-MSC can give good results when applied within the first 3 months after methyl alcohol intoxication.

WJ-MSC: A source of allogenic growth factors and neurotrophins.

MAGNOVISION™: Electromagnetic stimulation and iontophoresis device. Accelerates neurotransmission
and synaptic transmissions by activating ion channels with neuromodulation. Electromagnetic stimulation
device also stimulates the WJ-MSCs in the subtenon space. Magnovision increases exosom degranulation of
WJ-MSCs. Exosomes contain growth factors and neurotrophins. Electromagnetic iontophoresis is
mandatory for the transport of growth factors and neurotrophins from the scleral pores to the choroidal
matrix and then to the subretinal region by tyrosin kinase receptors. 10 sessions of MAGNOVISION after WJ-
MSC in 2 weeks then monthly 1 session for 6 months

Anterior Ischemic Optic Neuropathy Treatment:

MANAGEMENT OF OPTIC NEUROPATHIES

Innovative solutions for ophthalmology.

Committed to improving vision and

empowering eye care professionals.

Our Company


About Us

Contact Us

MagnoVision™

Contact


info@bioretina.com.tr

+90 (312) 235 85 10

+90 (530) 321 75 90

Erler Mah. Dumlupınar Bulvarı Üstün
Dekocity İş Merkezi No:348/68
Etimesgut/ANKARA/TÜRKİYE